AILERON THERAPEUTICS INC (ALRN) Stock Price & Overview
NASDAQ:ALRN • US00887A2042
Current stock price
The current stock price of ALRN is 2.11 USD. Today ALRN is up by 9.33%. In the past month the price decreased by -1.4%. In the past year, price decreased by -46.38%.
ALRN Key Statistics
- Market Cap
- 45.724M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.12
- Dividend Yield
- N/A
ALRN Stock Performance
ALRN Stock Chart
ALRN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ALRN. When comparing the yearly performance of all stocks, ALRN is a bad performer in the overall market: 94.93% of all stocks are doing better.
ALRN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALRN. The financial health of ALRN is average, but there are quite some concerns on its profitability.
ALRN Earnings
ALRN Forecast & Estimates
8 analysts have analysed ALRN and the average price target is 13.26 USD. This implies a price increase of 528.44% is expected in the next year compared to the current price of 2.11.
ALRN Groups
Sector & Classification
ALRN Financial Highlights
Over the last trailing twelve months ALRN reported a non-GAAP Earnings per Share(EPS) of -3.12. The EPS decreased by -9.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.06% | ||
| ROE | -30.71% | ||
| Debt/Equity | 0 |
ALRN Ownership
ALRN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.81 | 391.561B | ||
| AMGN | AMGEN INC | 15.82 | 197.434B | ||
| GILD | GILEAD SCIENCES INC | 16.34 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.86 | 118.403B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.24 | 80.021B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.94 | 42.294B | ||
| INSM | INSMED INC | N/A | 31.169B | ||
| NTRA | NATERA INC | N/A | 28.017B | ||
| BIIB | BIOGEN INC | 11.52 | 26.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 23.418B | ||
| MRNA | MODERNA INC | N/A | 21.054B | ||
| EXAS | EXACT SCIENCES CORP | 341.95 | 19.824B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.619B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALRN
Company Profile
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2017-06-29. The firm is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. The company has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Company Info
IPO: 2017-06-29
AILERON THERAPEUTICS INC
12407 N. Mopac Expy., Suite 250 #390
Austin TEXAS 02472 US
CEO: Manuel C. Alves Aivado
Employees: 15
Phone: 17378021989
AILERON THERAPEUTICS INC / ALRN FAQ
Can you describe the business of AILERON THERAPEUTICS INC?
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2017-06-29. The firm is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. The company has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
What is the stock price of AILERON THERAPEUTICS INC today?
The current stock price of ALRN is 2.11 USD. The price increased by 9.33% in the last trading session.
Does AILERON THERAPEUTICS INC pay dividends?
ALRN does not pay a dividend.
What is the ChartMill rating of AILERON THERAPEUTICS INC stock?
ALRN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of AILERON THERAPEUTICS INC (ALRN)?
AILERON THERAPEUTICS INC (ALRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.12).